Replies to post #132777 on Biotech Values

[genisi]

Baxter's Aralast and Kamada's Glassia are also being studied in the alpha-1 antitrypsin (AAT) treatment in type 1 diabetes area:

http://clinicaltrials.gov/ct2/results?term=aat+type+1+diabetes

Haven't checked the IP state yet, figured it's too early...

Edite: just noticed the AAT in Omni's study is actually Aralast, so one less competitor to worry about.